A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Recruiting now Phase 2 NCT07073820
Run by Pfizer · for 18 and older · All sexes
What this study is about
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Who can join (things the study team will check)
This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * do not have worsening or hospitalization for worsening PAH during the qualifying study. * not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH. * do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study. * not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem). * not currently prescribed or taking medicines called as GLP-1 agonist.…
Where this trial is running
- UC Davis Health Medical Center, Sacramento, California, United States
- UCSF Health St. Mary's Hospital, San Francisco, California, United States
- Heart and Vascular Center, San Francisco, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Norton Hospital, Louisville, Kentucky, United States
- Norton Pulmonary Specialists, Louisville, Kentucky, United States
- Mount Sinai Hospital, New York, New York, United States
- Clinical Trials Unit at Eastowne Medical Office Building, Chapel Hill, North Carolina, United States
- Pulmonary Hypertension Clinical Trials Office at Eastowne, Chapel Hill, North Carolina, United States
- Pulmonary Specialty Clinic at Eastowne Medical Office Building, Chapel Hill, North Carolina, United States
- UNC Hospitals, Chapel Hill, North Carolina, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
+ 36 more sites.
Who to contact
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07073820.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.